258 related articles for article (PubMed ID: 34378178)
1. Chronic liver graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients during tapering or after stopping calcineurin inhibitors.
Yoshimura K; Kimura SI; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Gomyo A; Matsumi S; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Kawamura K; Sato M; Terasako-Saito K; Tanihara A; Nakasone H; Kako S; Kanda Y
Int J Hematol; 2021 Dec; 114(6):674-681. PubMed ID: 34378178
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.
Chen CT; Liu CY; Yu YB; Liu CJ; Hsiao LT; Gau JP; Chiou TJ; Liu JH; Liu YC
PLoS One; 2017; 12(9):e0185210. PubMed ID: 28934311
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroids as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplant recipients with calcineurin inhibitor intolerance.
Puckrin R; Kwan ACF; Blosser N; Leyshon C; Duggan P; Daly A; Zepeda V; Stewart D; Chaudhry A; Storek J; Jamani K
Cytotherapy; 2023 Oct; 25(10):1101-1106. PubMed ID: 37306643
[TBL] [Abstract][Full Text] [Related]
4. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
5. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
7. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
8. [Liver biopsy in the management of liver dysfunction after allogeneic hematopoietic stem-cell transplantation].
Chen H; Huang XJ; Liu KY; Xu LP; Wang H; Liu DH; Lu J; Lu DP
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3062-6. PubMed ID: 16324408
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
12. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
13. Liver disease during and after hematopoietic stem cell transplantation in adults: a single-center Egyptian experience.
Abdelbary H; Magdy R; Moussa M; Abdelmoaty I
J Egypt Natl Canc Inst; 2020 Feb; 32(1):11. PubMed ID: 32372257
[TBL] [Abstract][Full Text] [Related]
14. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors.
Kang JM; Kim YJ; Kim JY; Cho EJ; Lee JH; Lee MH; Lee SH; Sung KW; Koo HH; Yoo KH
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1091-8. PubMed ID: 25708217
[TBL] [Abstract][Full Text] [Related]
15. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.
Ram R; Storer B; Mielcarek M; Sandmaier BM; Maloney DG; Martin PJ; Flowers ME; Chua BK; Rotta M; Storb R
Biol Blood Marrow Transplant; 2012 Mar; 18(3):414-22. PubMed ID: 21875504
[TBL] [Abstract][Full Text] [Related]
16. Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation.
Zhang H
Transfus Apher Sci; 2020 Jun; 59(3):102743. PubMed ID: 32139282
[TBL] [Abstract][Full Text] [Related]
17. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
19. Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes.
Novitzky-Basso I; AlHayli S; Shin E; Pasic I; Al-Shaibani Z; Lam W; Law A; Michelis FV; Gerbitz A; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Eur J Haematol; 2021 Apr; 106(4):508-519. PubMed ID: 33421199
[TBL] [Abstract][Full Text] [Related]
20. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
Modi A; Rybicki L; Majhail NS; Mossad SB
Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
